Content about Biotechnology

July 20, 2010
Decision Resources: Only half of payers support biosimilar substitution

Biosimilars may have cleared their biggest stretch of wilderness thanks to their inclusion in the...

July 18, 2010
Tidmarsh joins Spectrum

Biotechnology company Spectrum Pharmaceuticals has appointed a new SVP, chief scientific officer and head of...

July 14, 2010
Watson inks deal with Itero

Watson Pharmaceuticals will work with a venture-backed firm to develop a biosimilar treatment for female...

June 27, 2010
FDA approves expanded use of Omnitrope

The Food and Drug Administrations has approved two new uses for what remains, thus far,...

June 13, 2010
Gilead patent for Ranexa challenged by Lupin

Indian generic drug maker Lupin is challenging a Gilead Sciences patent for a drug that...

June 7, 2010
HDMA fetes leading drug, consumer product makers at inaugural business leadership event

The wholesale drug industry’s leading trade group tapped 10 pharmaceutical and consumer product manufacturers this...

June 6, 2010
On top of generics industry losses, GPhA loses CEO

After nearly a decade at the helm, Generic Pharmaceutical Association president and CEO Kathleen Jaeger...

May 24, 2010
Report: Teva recruits patients for Rituxan biosimilar trial

Generic drug maker Teva Pharmaceutical Industries isn’t holding back in its effort to push into...

May 20, 2010
Abbott purchases healthcare solutions provider

Abbott aims to become the top drug maker in India with the purchase of the...

May 16, 2010
IMS: ‘Pharmerging’ to propel Rx growth farther

Pharmaceuticals are expected to become a global market worth more than $1 trillion within four...

May 13, 2010
Report: Teva may benefit from health-reform law

Teva Pharmaceutical Industries could get a lot of business thanks to the health-reform law, according...

May 9, 2010
Genentech, Evotec to collaborate on drug development

U.S. biotechnology company Genentech and German drug maker Evotec hope to develop drugs using Evotec’s...

May 6, 2010
Pfizer gets a boost from Wyeth, specialty drugs in Q1

Pfizer reported $16.8 billion in revenues for first quarter 2010, a 54% increase over first...

March 29, 2010
Sandoz, GPhA weigh in on follow-on biologics provision

Many people have a lot to say about the recently passed healthcare bill, but generic...

March 21, 2010
PhRMA, BIO, GPhA weigh in on healthcare-reform bill passage

While calling it “not perfect,” an organization representing the country’s drug manufacturers called the healthcare-reform...

March 9, 2010
Solazyme, Unilever pen R&D deal

Solazyme, a renewable oil and bioproducts company, has inked a research and development agreement with...

March 4, 2010
Biosimilars could bring down specialty drug spending

If Medicare Part D is to remain solvent in the future, then lawmakers may want...

WHAT IT MEANS AND WHY IT'S IMPORTANT If Medicare Part D is to remain solvent in the future, then lawmakers may want to take a closer look at the more than 10% of spending on drugs under the program that has gone toward specialty drugs — some of the most expensive drugs on the market — and find ways to come up with cheaper alternatives.

March 2, 2010
GPhA: GAO report highlights need for availability of biogenerics

An organization representing the generic drug industry is holding up a recent report by the...

February 4, 2010
GSK may venture into rare disease treatments

GlaxoSmithKline has identified more than 5,500 rare diseases it could potentially target as part of...

February 1, 2010
FDA accepts approval application for Teva's Neutroval

The Food and Drug Administration has accepted a regulatory approval application from Teva Pharmaceutical Industries...

January 26, 2010
Lumene develops new anti-aging creams

Lumene, a beauty brand from Finland, has launched for 2010 its new ExCELLent future deep...

January 19, 2010
Governors urge preservation of current biosimilars legislation

Six governors are hoping to thwart an attempt by the Obama administration to eliminate language...

January 14, 2010
Senators push for 12-year exclusivity model for biosimilars

As the House and Senate fuse their respective healthcare-reform bills into one, a push has...

January 11, 2010
AmerisourceBergen launches expanded generic pharmaceuticals program

AmerisourceBergen announced a new program for long-term care pharmacies and an expanded program for retail...

August 20, 2009
Teva launches ‘Patient First’ project

Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody”...

NEW YORK Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody” means, but they know that battling a chronic disease can be a frightening and financially devastating prospect. Teva’s new TV campaign is a very sobering reminder of what many already know at a time when all of America is focused on fixing health care.